EPIX Pharmaceuticals, Inc. Announces South Korean Approval of Vasovist(R); Novel Contrast Agent Now Approved for Marketing in 34 Countries

LEXINGTON, Mass.--(BUSINESS WIRE)--EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, announced today that its novel blood pool magnetic resonance angiography (MRA) agent, Vasovist (gadofosveset trisodium) has been approved for marketing in South Korea.